Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for central nervous system disorders with neuronal imbalance. Its lead product candidates are PRAX-114 and PRAX-944, both of which are in Phase IIa clinical trial for treating major depressive disorder and essential tremor, respectively. The company is also developing additional products, has collaboration agreements with various organizations, and was incorporated in 2015 and is headquartered in Boston, Massachusetts.